Hosted on MSN2mon
Olaparib could be a safe, effective maintenance therapy in some ovarian cancer patientsA retrospective cohort study investigated the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer ...
However, the approaches within these trials resemble the Olaparib trials ... to be published. Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of ...
In early June, clinical results with BiPar's experimental drug BSI-201 and AstraZeneca's small-molecule PARP inhibitor olaparib were presented ... of cancer cells. PARP-1 is an enzyme directly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback